Technology

Artificial Intelligence Big Data Cloud Computing Cyber Security Data Management Electronics Enterprise & Network Technology Financial Technology Hardware Mobile & Wireless Nanotechnology Semiconductor Software Telecommunications
News Release Digital Asset Direct

Classiq and Quantum Intelligence Corp (QIC, Korea) Partner On Quantum Accelerated Drug Development

Classiq Technologies

Classiq, a leading quantum computing software company, and Quantum Intelligence Corp. ( QIC, Korea ) today announced the launch of innovative joint research to accelerate drug development by applying quantum computing to pharmacology. The collaboration is under the auspices of Classiq’s Quantum Computing For Life Sciences & Healthcare Center, launched with NVIDIA last year. This new partnership is dedicated to utilizing the Classiq platform to explore the use of quantum computing in pharmacology for a wide range of predictive and analytical applications. This includes the discovery and design of novel drug candidates as well as the prediction of potential side effects and interactions. The partnership focuses on significantly enhancing the efficiency and accuracy of drug development by integrating Classiq's quantum computing platform with QIC's drug development platform. “Quantum Intelligence diverges from the traditional route of biopharmaceutical companies, positioning itself more as a platform company powered by quantum and AI technology,” stated QIC's CEO, Hwanho Choi, MD., PhD. “Through this unique collaborative approach, we aim to precisely identify potential side effects early on, reducing risks across all stages of drug development and clinical trials.” QIC, a South Korean startup pioneering the QUEST-ADMET platform based on quantum computing and AI technologies, targets prediction of compound properties through electronic charge distribution algorithms, to efficiently assess therapeutic solution efficacy and safety of drug candidates. Classiq offers a leading quantum development platform with unique technology enabling high-level abstraction that simplifies and accelerates development of efficient complex quantum software and applications. The Classiq platform’s built-in functions, GitHub repository and seamless execution on quantum computing hardware, will be key components in the research to develop pharmacology applications for research. “This agreement marks a significant step towards a new era of accelerated drug development using quantum computing technology,” said Classiq’s CEO Nir Minerbi. “By combining Classiq's quantum computing technology with QIC's drug development platform, we target significant improvements in the efficiency and accuracy of drug development.” About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking users from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and website, www.classiq.io to learn more. About Quantum Intelligence Corp. (QIC) Founded in 2020 by CEO Dr. Choi Hwanho and CTO Dr. Kang Hong-seok, Quantum Intelligence Corp. (QIC), based in Seoul, South Korea, is at the forefront of integrating quantum computing with artificial intelligence to revolutionize drug discovery. Using its advanced QUEST-ADMET platform and the Quantum-Dock module, QIC aims to outperform conventional drug development approaches in both accuracy and speed, offering highly precise predictions of drug efficacy and safety. QIC's global expansion is supported by strategic partnerships, including collaborations with Oxford Quantum Circuits (UK), Quandela (France), and QuEra Computing (US), alongside a joint venture with 48Hour Discovery (Canada). These partnerships enhance QIC's presence in key North American, European and Asian markets. The collaborations are aimed at improving pharmacological predictions, discovering new drug candidates and investigating metalloprotein-ligand interactions and pharmacokinetics. Beyond healthcare, QIC is also exploring quantum computing's potential in the financial sector, aiming to transform algorithmic trading, risk analysis and asset management. QIC's diverse team of experts in quantum physics, molecular modeling and AI is committed to driving innovations that optimize the drug development process. These efforts have established QIC as a prospective leader in quantum drug discovery, aiming to reduce development costs and timelines while improving drug safety and efficacy. The company's strategy to license out drug candidates developed with its quantum computing technology marks a paradigm shift in the pharmaceutical industry, underscoring Quantum Intelligence's potential for significant growth. Contact Details Rainier Communications on behalf of Classiq Michelle Allard McMahon classiqPR@rainierco.com Quantum Intelligence Corp. (QIC) Byung-Hoon Kim, Operations Manager hoon.kim@qic.ai Company Website http://www.classiq.io/

April 04, 2024 08:00 AM Eastern Daylight Time

Bacula Systems Corp Appoints Aristide Caraccio as President & CEO

Bacula Systems

Expanding its leadership in high security backup and recovery for HPC and demanding IT environments, Bacula Systems today named Aristide Caraccio, its Senior VP of Sales and Marketing, as President & CEO of Bacula Systems Corp. “Aristide is a dynamic, values-driven business leader who has a diverse background of experiences and an excellent track record of delivery in the IT industry. He has led Bacula’s sales and marketing activities worldwide for some years now and helped build the industry leading reputation we have for customer satisfaction in some of the world’s most security conscious and demanding organizations worldwide. The Board looks to Aristide to further develop the organization to realize the full potential of Bacula Systems Corp, delivering growth and value for its customers, employees and shareholders”, said Frank Barker, Chairman of Bacula Systems SA. Caraccio joined Bacula in 2011, and has been instrumental in developing Bacula’s customer base in the United States and globally, including large organizations such as NASA, Warner Bros. Discovery and Navisite. “I am excited by Bacula’s unique ability to protect large, complex and high performance IT environments, and its disruptive positioning in helping users to avoid vendor lock-in. The opportunity for Bacula has never been bigger than it is today and I am honored to lead Bacula Systems Corp as it helps organizations to modernize their backup strategy, lower costs, and achieve much better protection against ransomware and other attacks”, said Caraccio. “I am delighted to have Aristide leading Bacula Systems Corp. His vision and drive will help us to bring a more secure, flexible, scalable, powerful and cost-effective backup and security solution to more customers so they can replace outdated and overpriced legacy backup systems. Aristide has the right industry and commercial knowledge to leverage our unique software and lead Bacula Systems Corp as it further develops market share in North America, Canada and Latin America”, said Gopal RajGuru, CEO of Bacula Systems SA. About Bacula Systems: Bacula Enterprise is a highly scalable backup and recovery software for large organizations, data centers and MSPs. www.baculasystems.com Contact Details Rob Morrison rob.morrison@baculasystems.com +41 21 641 60 80 rob.morrison@baculasystems.com Company Website https://www.baculasystems.com/

April 04, 2024 07:17 AM Eastern Daylight Time

Effortless Organization: Dola AI Sets New Standard for Personal Assistants

Rev Up Marketers

San Francisco, California, United States, 2nd Apr 2024 - Prepare for the revolution of the personal assistant experience with Dola AI, a groundbreaking AI assistant powered by GPT-4. Created by a talented team with a track record of founding and building Dola AI distinguishes itself by offering cutting-edge technology that provides organization capabilities with minimal user effort. Dola AI simplifies the process of staying organized by seamlessly integrating with users’ messenger apps. Whether it's text, images, or voice messages, Dola effortlessly transforms users’ communications into actionable plans and calendar alerts. Key features of Dola AI include its multi-modal functionality, AI-driven alerts and reminders, streamlined handling of complex tasks, seamless integration without the need for downloads, group chat support, and synchronization across devices. Beneficiaries of Dola AI range from top-tier executives and executive assistants seeking to streamline their schedules to all individuals aiming to boost productivity effortlessly. Additionally, workgroups, family chat groups, and social circles can leverage Dola AI to enhance communication and organization. As users continue to engage with Dola, the AI will progressively learn more about their preferences, habits, and unique requirements. Leveraging advanced machine learning algorithms, Dola will adapt and tailor the personal assistant experience to suit the individual needs of each user. This personalized approach ensures that Dola becomes increasingly intuitive and adept at anticipating user preferences, streamlining tasks, and providing timely assistance. Dola's evolution into the future will see it expanding its assistant functions to encompass a comprehensive array of tasks. The team envisions Dola not only seamlessly and reliably managing users' schedules but also actively performing other tasks of a personal assistant. Data security and user privacy are also paramount for Dola, and the company adheres to the most stringent security and privacy frameworks globally. Dola's commitment to safeguarding user information extends to compliance with leading industry standards and regulations, ensuring that users' data remains protected at all times. The team behind Dola is committed to pushing the boundaries of AI technology to empower users with a truly proactive and versatile personal assistant. With continuous updates and advancements, Dola will become an indispensable tool for managing both professional and personal tasks, revolutionizing the way users navigate their daily lives. Dola AI is available free on iMessage, WhatsApp, Telegram, and Line, offering users unparalleled convenience and accessibility almost instantly. For more information and to experience the future of personal assistant perfection, please visit https://heydola.com Contact Details Orion Arm Pte. Ltd. 2024 Robert Zheng acc_press@heydola.com Company Website https://heydola.com

April 03, 2024 05:50 PM Eastern Daylight Time

Image

Upcoming ETF Verdict Spurs Crypto Buy Pressure: Bitcoin, Ethereum, and Raboo Set for Further Gains

Total Media

As anticipation mounts with the upcoming ETF verdict, the crypto market sees a surge in buy pressure. Bitcoin and Ethereum, already household names, are joined by the emerging contender Raboo, currently in the limelight with its presale. Priced at a mere $0.003, Raboo is not just any token—it's forecasted to skyrocket by 100x in 2024. With analysts buzzing over the Bitcoin price prediction and the potential approval of an Ethereum ETF, the stage is set for monumental gains. Raboo, in particular, stands at a pivotal 233% growth expectation during its presale, heralding an explosive entry into the crypto scene. Bitcoin's wild March: Highs, lows, and the unstoppable rise to the top Bitcoin's dance on the financial stage has been nothing short of a thriller this March. Hitting an all-time high, Bitcoin swiftly took a 10% tumble, causing a frenzy of over $1 billion in crypto liquidations. Yet, amidst this rollercoaster, the crypto titan stands resilient, buoyed by news of BlackRock's Bitcoin ETF potentially eclipsing Grayscale's holdings, setting the stage for a seismic shift in institutional holdings. With Bitcoin's halving on the horizon, the buzz around its future Bitcoin’s price performance intensifies, keeping enthusiasts on the edge of their seats. This unpredictability, combined with expert Bitcoin price predictions hinting towards $100,000, teases a future where Bitcoin's influence only grows stronger. Ethereum: Skyrocketing prices and groundbreaking upgrades unleashed Keeping up with the Bitcoin price prediction is Ethereum which has seen its recent trajectory sail past $3,500, invigorated by the upcoming potential approval of the Ethereum ETFs. The anticipation around Ethereum and its evolving ecosystem, including pivotal upgrades and market enthusiasm, positions Ethereum for an exhilarating leap forward. Ethereum, standing at the precipice of innovation, continues to captivate investors and developers alike. Raboo rises: A meme revolution unleashed, setting the digital world ablaze Raboo is set to redefine the meme landscape by marrying social-fi and AI, creating a dynamic arena for meme aficionados. This platform transforms users into vital contributors within a flourishing ecosystem of NFTs and AI-enhanced memes, fostering an unprecedented level of creative engagement. Raboo's narrative, a digital realm in 3024 overrun by mundane memes, sets the stage for its rise as the savior of digital creativity, wielding an AI capable of evolving and curating high-quality content. The RABT token, beyond mere trading, acts as the backbone of this community, incentivizing participation through challenges and exclusive giveaways. The anticipation around its presale, priced attractively at $0.003, hints at a 366% growth potential before launch, aiming for a spectacular 100x increase on debut. Raboo's vision extends to eclipsing giants like Shiba Inu and Dogecoin, propelled by a unique tokenomics strategy, including a deliberate crypto burn to enhance value. With features like Rabooscan and exclusive NFTs for early supporters, Raboo is a unique long-term investment opportunity for crypto enthusiasts. Conclusion As the crypto market heats up with the impending ETF decisions for Ethereum, the spotlight intensifies on Raboo. With its presale quickly selling out, Raboo represents a fleeting, golden opportunity for early investors. This surge of interest underscores the urgency and potential of Raboo, alongside stalwarts like Bitcoin and Ethereum, as they head toward unprecedented growth. You can participate in the Raboo presale here. Contact Details Total Media Solutions media@Totalsolutionspr.io

April 03, 2024 03:25 PM Eastern Daylight Time

Image

AdvicePay 2024 Fee-for-Service Industry Trend Report Shows Marked Increase in Fees Advisors Charge for Fee-Based Financial Planning

AdvicePay

In 2023, financial advisors saw an increase in the amount of fees they were able to charge clients who engaged them in fee-for-service financial planning, according to the 2024 Fee-for-Service Industry Trend Report from AdvicePay, the industry-leading platform for processing payments and overseeing compliance of fee-for-service financial planning. Last year, monthly recurring subscriptions for planning fees rose to $265 per client, up 6% from 2022. Quarterly recurring subscriptions averaged $968 per client, up 1.6%. One-time payments rose 6.7% to $1,578, according to AdvicePay’s proprietary data. Financial advisors continue to prefer subscription models. According to the report, 83% of all invoices sent through AdvicePay were for subscriptions, and 74% of all invoices were monthly recurring. Half of all advisors bill their clients monthly, while 22% bill quarterly. Advisors reported that clients remain receptive to fee-for-service financial planning because it aligns with their accustomed payment models for other subscription services, such as Netflix. This approach enables them to conveniently compensate their advisors using their cash flow while adding an extra layer of transparency. “We continue to find that there are more consumers looking for financial planning than there are financial planners to provide that fee-for-service offering,” said Alan Moore, Co-Founder and Chief Executive Officer of AdvicePay. “What’s more, the retention rates are extremely high in an ongoing financial planning relationship, and the latest data show that the economics continue to be very favorable.” According to research issued by Cerulli Associates and the Securities Industry and Financial Markets Association (SIFMA), there has been a notable shift, with 63% of investors expressing a willingness to pay for advice, up from the 38% reported in 2009. The research also highlights a heightened demand for personalized, comprehensive advice with a focus on formal financial plans rising from 38% to 54% over the past 14 years. Most advisors surveyed offer additional services outside of fee-based planning. According to the data, 88.4% offer investment management, while 82.1% provide tax planning. Increasingly, more advisors are offering guidance on held-away accounts like 401(k)s, with 63.1% of financial advisors reporting this is a service they provide. The 2024 AdvicePay Fee-for-Service Industry Trend Report draws upon insights gleaned from over 380,000 fee-for-service financial planning transactions conducted through the company’s platform. To receive a copy of the full report, please visit https://info.advicepay.com/trends. About AdvicePay Established by well-known financial advisors Michael Kitces and Alan Moore, AdvicePay is the industry-leading billing and payment workflow solution created specifically for fee-for-service financial planning. Financial services firms and their advisors benefit from efficient workflows designed exclusively to support their fee-for-service financial planning revenue, including up-to-date compliance and data security management, all in one unified platform. Contact Details Shannon Beck +1 406-412-2047 media@advicepay.com Company Website https://advicepay.com/

April 03, 2024 01:22 PM Eastern Daylight Time

MedCognetics Secures Groundbreaking Patent for Inclusive, Unbiased Medical Imaging AI Technology in Mammography

MedCognetics

In a significant stride towards equitable healthcare technology, MedCognetics, Inc., a company focusing on medical imaging AI, today announced it has been awarded patent number 11,948,297 by the United States Patent and Trademark Office (USPTO). The patent covers architectural strategies and methodologies for achieving unbiased AI in breast imaging. This innovation is backed by MedCognetics’ peer-reviewed publications in industry conferences such as the Radiological Society North America (RSNA) 2023, the European Society of Radiology (ESR) 2024, and a grant from the National Institutes of Health (NIH). This breakthrough is set to redefine the development of AI in the medical field ensuring MedCognetics’ algorithms maintain high performance across different patient demographics, thereby guaranteeing consistent, fair, superior patient outcomes. "This patent is a reflection of our team's focused pursuit of innovation and commitment to inclusivity,” said Ron Nag, CEO of MedCognetics, Inc. “Our technology is not just about improving patient outcomes through earlier and more accurate diagnoses; the focus is on fostering equality in technological development and ensuring universal access to advancements in healthcare systems worldwide. We remain dedicated to progressing in the field of unbiased medical imaging technology.” MedCognetics is actively engaged in partnerships with leading healthcare institutions and research organizations to bring its patented AI technology into clinical practice, aiming for widespread patient benefit from these advancements at the earliest. Full details of the allowance are listed in the Issue Notification Certificate issued by the USPTO. For further information about MedCognetics and its pioneering medical imaging AI technology, please visit www.medcognetics.com. About MedCognetics, Inc. MedCognetics provides an advanced AI software platform that integrates into radiology workflow. In addition, the AI algorithm is trained on a diverse global patient dataset to mitigate data biasing. The future of AI in healthcare is unbiased services and MedCognetics is at the forefront of creating a more predictable medical outcome and ultimately saving lives. Founded in 2020, the company is based in Dallas, Texas. For more information, please visit our website at www.medcognetics.com. Contact Details ANW Networks Alicia Nieva-Woodgate +1 415-515-0866 alicia@anwnetworks.com Company Website https://www.medcognetics.com

April 03, 2024 11:30 AM Eastern Daylight Time

Nextech3D.ai protects intellectual property with a patent for generating 3D models from 2D images

Nextech3D.AI

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce a significant milestone for the company as the U.S. Patent and Trademark Office (USPTO) officially issued a patent for their technology to generate three-dimensional models from two-dimensional images. Gappelberg emphasized the importance of this patent in the realm of artificial intelligence (AI) and 2D to 3D model generation, describing it as a pivotal patent for the 3D modeling industry. He highlighted that this patent adds substantial value to Nextech3D.ai and positions the company as one of the technology leaders in the field of converting 2D photos to 3D models using AI. The issuance of this patent provides Nextech3D.ai with a competitive advantage, setting them apart from other companies involved in 3D model generation. Gappelberg expressed confidence that this patent, along with a second AI patent issuance and seven additional patents filed, strengthens the company's position and builds a moat around their 3D model-making business for e-commerce. With a focus on both industry expertise and intellectual property, including GPT AI-powered 3D model generation, Nextech3D.ai aims to increase shareholder value by investing in 3D-AI GPT patents and solutions. Gappelberg emphasized that this second AI patent approval reinforces and validates the company's commitment to innovation and generating substantial revenue through 3D modeling. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

April 03, 2024 11:20 AM Eastern Daylight Time

Video

PathAI Announces Research Presentations at the 2024 AACR Annual Meeting

PathAI

PathAI, Inc., a leading AI-powered precision pathology company, today announced it will present research from its portfolio of oncology products at the AACR Annual Meeting on April 7-10, 2024, in San Diego, CA. The research demonstrates how machine learning models developed to characterize the tumor microenvironment (TME) from routine hematoxylin and eosin (H&E)-stained whole slide images (WSIs) can be used to advance biomarker development and precision medicine strategies. The presentations include new research leveraging PathAI’s pan-tumor foundation models and its commercially available product, PathExplore 1, to identify key histologic features associated with molecular signatures and patient response to therapy. Highlights: Researchers deployed PathExplore on HNSCC and NSCLC samples to characterize the cell and tissue composition of the tumor microenvironment, as well as compute immune phenotypes directly from H&E WSI. (Poster #905 ) Researchers from Incendia Therapeutics developed a continuous scoring method for Discoidin Domain Receptor 1 (DDR1), which revealed widespread immune exclusion in tumors based on the spatial distribution of lymphocytes, CD8+ T cells, and CD45+ immune cells from H&E and mIF images. DDR1 is highly expressed in epithelial cancers and has been implicated in tumor growth, invasion, and lack of response to therapy. The immune exclusion score correlates with DDR1 mRNA and protein expression. The study provides additional insight into the role of DDR1 in human cancers and may be useful in selecting indications and stratifying patients for DDR1-targeted therapies. (Poster #2916 ) Using unsupervised learning driven by PathExplore’s features and a novel collagen fiber detection imaging technology, researchers discovered three distinct phenotypes of cancer associated stroma (CAS) that had distinct patterns of association with survival and gene expression signatures. Two of them were enriched in collagen fiber density as well as in density of fibroblasts, while the third phenotype had the highest density of immune cells, providing a categorization of different types of CAS-tumor interaction that may be useful for patient stratification. (Poster #4912 ) Using AI-powered models from PathAI, Foundation Medicine researchers investigated digital pathology TME features of immunotherapy outcomes among NSCLC patients within a real-world dataset from the Flatiron Health-Foundation Medicine Clinico-Genomic Database. These results indicate that the composition of the TME assessed via digital pathology may have utility in identifying NSCLC patients who will respond to first-line immune checkpoint inhibitors beyond the established immunotherapy biomarkers. (Poster #4969 ) In collaboration with EMD Serono, AI-powered TME models from PathAI were used to analyze H&E WSI of NSCLC from a randomized Phase 3 trial directly comparing two immunotherapies. Researchers compared cell abundance features with gene expression data from the same samples and found that immune and stromal cell abundance features were associated with expression of genes in relevant cellular pathways, confirming the biological relevance of our cellular features. In analyzing the features alongside the clinical data from the retrospective study, researchers identified candidate prognostic immunotherapy biomarkers. (Poster #6179 ) Researchers from Incendia Therapeutics illustrated that morphologic features derived from H&E images using PathExplore can be effective predictors of CD8-defined immune exclusion, providing an option for patient stratification by immune phenotype using widely available H&E images. The features and direction of association align with prior knowledge of the mechanism or manifestations of immune exclusion or infiltration in the TME, including the relative density of lymphocytes in tumor and stroma. (Poster #7392 ) PathAI’s pan-tumor foundation models were used to identify tissue regions and cell types on H&E WSI to quantify tumor purity across multiple tumor types. Model-derived tumor purity estimates were compared to three orthogonal molecular methods of purity and found to correlate across disease indications. These results provide evidence of how AI can improve the efficiency of molecular testing and enhance precision diagnostic strategies. (Poster #7402 ) Follow PathAI on LinkedIn and X for more updates from #AACR24 and visit us in person at booth #1549. 1 PathExplore is For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

April 03, 2024 10:00 AM Eastern Daylight Time

Analyst Crypto Jebb Urges To Buy Ethereum Right Now! Cardano Left in the Dust As KangaMoon Bull Run Continues!

Kangamoon

Renowned analyst Crypto Jebb has been talking about Ethereum (ETH) a lot lately and people are starting to listen. Meanwhile, Cardano (ADA) has been outshined by many altcoins like KangaMoon (KANG), which is on a massive bull run. This Stage 5 presale star has already provided early buyers with 291% ROI, causing many experts to hint at a $0.5 price in 2024. Crypto Jebb: Ethereum Price Will Moonshot Recently, Ethereum (ETH) has been on an uptrend. Over the past 30 days, the Ethereum price soared from $3,409 to $3,557. During that time, its market cap increased from $410B to $427B. According to crypto analyst Crypto Jebb, this bullish trend will continue for the Ethereum crypto. He forecasts a potential 10x on ETH within the next ten years. This altcoin's technical analysis also shows a bullish future. For instance, Ethereum is now trading above its 100— and 200-day EMAs. Additionally, 25 technical indicators are showing green for ETH. As a result, experts have made a bullish Ethereum price prediction. They foresee this altcoin's price hitting $4,489 within Q2 of 2024. Cardano (ADA): Trading in the Red On the other hand, Cardano (ADA) has been trading in the red. According to CoinMarketCap data, the Cardano price sank from $0.73 to $0.63 over the past month. In that period, its market cap also fell from $26B to $22.46B. However, the technical analysis for this altcoin paints a different picture. Notably, the Cardano coin is trading above its 100 and 200-day EMAs. Additionally, this altcoin now has over 20 technical indicators showing bullish signs. Due to all these reasons, market analysts have made a bullish Cardano price prediction - a rise to $0.86 within Q2 of 2024. KangaMoon (KANG): Becoming One of the Altcoins To Watch While Ethereum and Cardano experience ups and downs, KangaMoon (KANG) has surfaced as an unexpected contender. This presale star has already soared by 291%, with 20,000 registered community members. Moreover, KangaMoon has raised over $3.9M and projects reaching $5M before April 2024 ends. Essentially, KangaMoon will develop a Play-to-Earn (P2E) game in which KANG will serve as the main in-game currency. With KANG, you can buy character upgrades or in-game items. Additionally, KANG holders gain exclusive access to challenges for extra tokens or in-game items. Another impressive part of KangaMoon is its dedication to cultivating an active community. As an example, users can earn free KANG tokens by being engaged members before the official launch. This has caused a significant surge in social media interaction as traders eagerly like, share and retweet KangaMoon's content. All these factors have helped KangaMoon obtain over 5,800 holders. Currently, one KANG token costs just $0.0196 - a 291% rise from its starting price of $0.005. Experts remain bullish as they forecast a rise to $0.5 once a Tier-1 CEX lists this altcoin in Q2 of 2024. This price prediction seems plausible with ties to the P2E gaming market, which will reach $885M by 2028. Will KangaMoon Rise Faster than Ethereum and Cardano? With its low $14M market cap, KangaMoon could outshine Ethereum and Cardano. This means it needs fewer new funds so the price can skyrocket faster. If you want to buy one of the top altcoins, sign up for its presale using the links below and get a 10% bonus. Discover the Exciting Opportunities of the KangaMoon (KANG) Presale Today! Website: https://Kangamoon.com/ Join Our Telegram Community: https://t.me/Kangamoonofficial Integrating GameFi and Play To EarnEmbark on your quest for glory. Assemble your champions, engage in epic battles or bet on your favorite fighters to earn $KANG tokens and exclusive rewards. Gain control of rare NFTs, unlock exclusive content and build alliances with fellow gamers as you ascend the ranks and leaderboards. Disclaimer: The following disclaimer is important to read and understand before engaging with Kangamoon, a play-to-earn meme coin. By accessing or participating in any activities related to Kangamoon, you acknowledge and accept the terms outlined below: 1 No Financial Advice: This whitepaper and any associated content do not constitute financial advice, investment recommendations, or solicitation to purchase Kangamoon tokens. The information provided is for informational purposes only. It is your responsibility to conduct thorough research and seek professional advice before making any financial decisions. 2 Volatility and Risks: Cryptocurrencies, including Kangamoon, are volatile and subject to significant price fluctuations. Investing in or holding Kangamoon tokens involves substantial risks, including the possibility of total loss. Past performance is not indicative of future results. 3 Regulatory Compliance: The regulatory environment surrounding cryptocurrencies is evolving and varies across jurisdictions. It is your responsibility to ensure compliance with applicable laws and regulations in your country or region before engaging with Kangamoon. 4 Uncertain Market: The market for meme coins and play-to-earn platforms is highly speculative and subject to rapid changes. There is no guarantee of market demand, liquidity, or utility for Kangamoon tokens. Token values may fluctuate drastically and may not reflect the intrinsic value of the project. By continuing to engage with Kangamoon, you acknowledge and accept the risks and limitations outlined in this disclaimer. You should only participate if you fully understand and are willing to assume these risks. Contact Details Kangamoon marketing@kangamoon.com Company Website https://kangamoon.com/

April 03, 2024 09:00 AM Central Daylight Time

Image

1 ... 83 84 85 86 87 ... 638